Literature DB >> 24388046

Phenotypic concordance in familial inflammatory bowel disease (IBD). Results of a nationwide IBD Spanish database.

Eduard Cabré1, Míriam Mañosa2, Valle García-Sánchez3, Ana Gutiérrez4, Elena Ricart5, Maria Esteve6, Jordi Guardiola7, Mariam Aguas8, Olga Merino9, Angel Ponferrada10, Javier P Gisbert11, Esther Garcia-Planella12, Gloria Ceña13, José L Cabriada14, Miguel Montoro15, Eugeni Domènech2.   

Abstract

BACKGROUND & AIMS: Disease outcome has been found to be poorer in familial inflammatory bowel disease (IBD) than in sporadic forms, but assessment of phenotypic concordance in familial IBD provided controversial results. We assessed the concordance for disease type and phenotypic features in IBD families.
METHODS: Patients with familial IBD were identified from the IBD Spanish database ENEIDA. Families in whom at least two members were in the database were selected for concordance analysis (κ index). Concordance for type of IBD [Crohn's disease (CD) vs. ulcerative colitis (UC)], as well as for disease extent, localization and behaviour, perianal disease, extraintestinal manifestations, and indicators of severe disease (i.e., need for immunosuppressors, biological agents, and surgery) for those pairs concordant for IBD type, were analyzed.
RESULTS: 798 out of 11,905 IBD patients (7%) in ENEIDA had familial history of IBD. Complete data of 107 families (231 patients and 144 consanguineous pairs) were available for concordance analyses. The youngest members of the pairs were diagnosed with IBD at a significantly younger age (p<0.001) than the oldest ones. Seventy-six percent of pairs matched up for the IBD type (κ=0.58; 95%CI: 0.42-0.73, moderate concordance). There was no relevant concordance for any of the phenotypic items assessed in both diseases.
CONCLUSIONS: Familial IBD is associated with diagnostic anticipation in younger individuals. Familial history does not allow predicting any phenotypic feature other than IBD type.
Copyright © 2013 European Crohn's and Colitis Organisation. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Concordance analysis; Crohn's disease; Familial aggregation; Inflammatory bowel disease; Ulcerative colitis

Mesh:

Year:  2013        PMID: 24388046     DOI: 10.1016/j.crohns.2013.12.005

Source DB:  PubMed          Journal:  J Crohns Colitis        ISSN: 1873-9946            Impact factor:   9.071


  7 in total

Review 1.  Host-microbiome interaction in Crohn's disease: A familiar or familial issue?

Authors:  Andrea Michielan; Renata D'Incà
Journal:  World J Gastrointest Pathophysiol       Date:  2015-11-15

2.  Disease severity and treatment requirements in familial inflammatory bowel disease.

Authors:  María Pilar Ballester; David Martí; Joan Tosca; Marta Maia Bosca-Watts; Ana Sanahuja; Pablo Navarro; Isabel Pascual; Rosario Antón; Francisco Mora; Miguel Mínguez
Journal:  Int J Colorectal Dis       Date:  2017-03-31       Impact factor: 2.571

3.  Research to the N-Power: The Strengths of Networked Clinical Collaboration in Spain.

Authors:  Adrian G McNicholl; Javier P Gisbert
Journal:  Am J Gastroenterol       Date:  2017-11-07       Impact factor: 10.864

4.  Clinical and Demographic Profile of Inflammatory Bowel Disease Patients in a Reference Center of São Paulo, Brazil.

Authors:  Tarcia Nogueira Ferreira Gomes; Fabio Silva de Azevedo; Marjorie Argollo; Sender Jankiel Miszputen; Orlando Ambrogini
Journal:  Clin Exp Gastroenterol       Date:  2021-03-17

5.  Conjugal inflammatory bowel disease: a systematic review and European survey.

Authors:  Maria Pia Costa-Santos; Catarina Frias-Gomes; António Oliveira; João Sabino; Miriam Mañosa; Pierre Ellul; Ana Sampaio; Luisa Avedano; Salvo Leone; Jean-Frédéric Colombel; Joana Torres
Journal:  Ann Gastroenterol       Date:  2021-02-26

Review 6.  Familial and ethnic risk in inflammatory bowel disease.

Authors:  Maria Pia Costa Santos; Catarina Gomes; Joana Torres
Journal:  Ann Gastroenterol       Date:  2017-10-26

7.  Exclusive enteral nutrition protects against inflammatory bowel disease by inhibiting NF‑κB activation through regulation of the p38/MSK1 pathway.

Authors:  Ting Yu; Qian Yu; Xiaotian Chen; Lixing Zhou; Yuming Wang; Chenggong Yu
Journal:  Int J Mol Med       Date:  2018-06-04       Impact factor: 4.101

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.